We previously demonstrated the benefit of DNA-based therapy assessment using patient-specific genomic fusion sequences for mesenchymal tumors including leukemia, lymphoma, and Ewing sarcoma (EWS) [25–28]. Here, EWSR1 is linked to mesenchymal cell neoplasm.